open access

Vol 9, No 4 (2005)
Prace oryginalne
Published online: 2005-08-05
Get Citation

The role of moxonidine in the treatment of vasovagal syncope and primary hypertension

Małgorzata Lelonek, Jan Henryk Goch
Nadciśnienie tętnicze 2005;9(4):276-284.

open access

Vol 9, No 4 (2005)
Prace oryginalne
Published online: 2005-08-05

Abstract

Background In pathophysiology of vasovagal syncope (VVS) participates the autonomic nervous system. VVS frequently coexists with hypertension. Pharmacological proceeding in this group of patients is peculiarly difficult. As well the autonomic nervous system participates in pathophysiology of hypertension. The effect of treatment on components of autonomic nervous system can be measured by heart rate variability (HRV). The aim of the study was the analysis of the effect of treatment with moxonidine in hypertensive patients with vasovagal syncope and analysis of HRV parameters.
Material and methods 40 patients (32% male, mean age 60 ± 10.8 years) with history of recurrent syncope and mild or moderate hypertension were involved in research. In control group were 20 patients (30% male, mean age 59 ± 11.4 years) with mild or moderate hypertension without syncope. In all patients were performed: the initial history, HRV analysis, ambulatory blood pressure monitoring and head-up tilt testing (HUTT) before and during the treatment of moxonidine.
Results In the patients with VVS and hypertension during the therapy of moxonidine significant reduce of number of syncope (p < 0.001), of prodromal symptoms (p < 0.01) and substantial reduce of positive outcome of HUTT (p < 0.001) were documented. Moreover in this group of patients no statistic differences in LF parameters after tilting in comparison to control group and before therapy were noted.
Conclusions Moxonidine beyond the hypotensive effect reduces frequency of syncope and elevated activity of sympathetic component in patients with vasovagal syncope and hypertension.

Abstract

Background In pathophysiology of vasovagal syncope (VVS) participates the autonomic nervous system. VVS frequently coexists with hypertension. Pharmacological proceeding in this group of patients is peculiarly difficult. As well the autonomic nervous system participates in pathophysiology of hypertension. The effect of treatment on components of autonomic nervous system can be measured by heart rate variability (HRV). The aim of the study was the analysis of the effect of treatment with moxonidine in hypertensive patients with vasovagal syncope and analysis of HRV parameters.
Material and methods 40 patients (32% male, mean age 60 ± 10.8 years) with history of recurrent syncope and mild or moderate hypertension were involved in research. In control group were 20 patients (30% male, mean age 59 ± 11.4 years) with mild or moderate hypertension without syncope. In all patients were performed: the initial history, HRV analysis, ambulatory blood pressure monitoring and head-up tilt testing (HUTT) before and during the treatment of moxonidine.
Results In the patients with VVS and hypertension during the therapy of moxonidine significant reduce of number of syncope (p < 0.001), of prodromal symptoms (p < 0.01) and substantial reduce of positive outcome of HUTT (p < 0.001) were documented. Moreover in this group of patients no statistic differences in LF parameters after tilting in comparison to control group and before therapy were noted.
Conclusions Moxonidine beyond the hypotensive effect reduces frequency of syncope and elevated activity of sympathetic component in patients with vasovagal syncope and hypertension.
Get Citation

Keywords

vasovagal syncope; hypertension; therapy; heart rate variability

About this article
Title

The role of moxonidine in the treatment of vasovagal syncope and primary hypertension

Journal

Arterial Hypertension

Issue

Vol 9, No 4 (2005)

Pages

276-284

Published online

2005-08-05

Bibliographic record

Nadciśnienie tętnicze 2005;9(4):276-284.

Keywords

vasovagal syncope
hypertension
therapy
heart rate variability

Authors

Małgorzata Lelonek
Jan Henryk Goch

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl